Cargando…

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study

Real-world evidence on the effectiveness of COVID-19 vaccines marketed in China against the Omicron BA.2.2 variant remains scarce. A case–control study was conducted to estimate the vaccine effectiveness (VE) of COVID-19 vaccines marketed in China (inactivated vaccines, an Ad5-nCoV vaccine, and a re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaqing, Wang, Yao, Hu, Chengyang, Xu, Pengpeng, Ma, Liguo, Liu, Lei, Sun, Jie, Liu, Yang, Yang, Hui, Pan, Fan, Hu, Jieying, Cao, Chengsong, Cheng, Kai, Gao, Dawei, Lyu, Yong, Qin, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088971/ https://www.ncbi.nlm.nih.gov/pubmed/36998173 http://dx.doi.org/10.1080/21645515.2023.2194189

Ejemplares similares

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections
por: Tso, Winnie W.Y., et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
por: Rissmann, Melanie, et al.
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections
por: Saade, Carla, et al.
Publicado: (2022)

Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain)
por: Ciuffreda, Laura, et al.
Publicado: (2023)

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
por: Bingula, Rea, et al.
Publicado: (2023)

Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China
por: Zheng, Liwei, et al.
Publicado: (2023)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023)

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants
por: Chen, Yuxin, et al.
Publicado: (2022)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)
por: Wang, Hongyu, et al.
Publicado: (2023)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees
por: Dapporto, Francesca, et al.
Publicado: (2022)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China
por: Yin, Zhiying, et al.
Publicado: (2023)

Genetic analysis of a SARS-CoV-2 Omicron variant from a Chinese traveller returning from overseas
por: Jia, Hongling, et al.
Publicado: (2022)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage
por: Liang, Ronghui, et al.
Publicado: (2022)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants
por: Wu, Dan, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants
por: de La Vega, Marc-Antoine, et al.
Publicado: (2023)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination
por: Wang, Miao, et al.
Publicado: (2022)

Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
por: Xu, Hongqin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g3f58tqko9biub1d4tob4jfgkk